Intas Pharma’s Romy® demonstrates high overall response rate

Dec 9, 2020

A new study indicates Intas Pharma’s romiplostim biosimilar Romy® has demonstrated a high overall response rate without adverse events in patients with immune thrombocytopenic purpura. Romy® has been approved in India.

Print Page Mail Article